What's Happening?
Leica Biosystems, a subsidiary of Danaher, has announced an expansion of its strategic collaboration with AstraZeneca and Daiichi Sankyo. This partnership aims to develop an immunohistochemistry (IHC) assay and image analysis algorithm specifically for
the TROP2 Normalized Membrane Ratio (NMR) biomarker in non-small cell lung cancer. The collaboration, initially announced in May 2025, leverages AstraZeneca's Quantitative Continuous Scoring (QCS) algorithm and Leica Biosystems' digital pathology solutions. This initiative is designed to create an end-to-end solution that assesses a novel biomarker incorporating both membrane and cytoplasmic expression. The goal is to advance digital and computational pathology tools, including AI-assisted algorithms, to identify patients most likely to benefit from targeted therapies. The collaboration will utilize Leica Biosystems' BOND RX research stainer, BOND-III clinical stainer, Aperio GT 450 scanner, and the Aperio HALO AP image management system to support the rapid development and deployment of computational image analysis algorithms.
Why It's Important?
This collaboration is significant as it represents a shift towards more precise and scalable approaches in cancer diagnostics, particularly in the field of precision medicine. By integrating digital and computational pathology tools, the partnership aims to enhance diagnostic precision beyond traditional methods. This could potentially lead to more effective targeted therapies for patients with non-small cell lung cancer, a common and challenging form of cancer. The use of AI and digital pathology solutions could streamline workflows and improve the accuracy of diagnoses, ultimately benefiting patients by providing more personalized treatment options. The collaboration also reflects a broader industry trend towards integrated digital ecosystems, which could transform how diagnostic tools are developed and deployed globally.
What's Next?
The collaboration will continue to focus on the development and global deployment of the TROP2 NMR algorithm through the Aperio AI Store, an open marketplace for AI and image analysis solutions. This will enable users to evaluate and deploy tools within a unified digital and computational pathology platform. As the partnership progresses, it is expected to further integrate AI and digital pathology into clinical workflows, potentially setting new standards for cancer diagnostics. The ongoing collaboration may also inspire similar partnerships across the industry, fostering innovation and improving patient outcomes in cancer care.
